A majority of Americans have experienced the frustration of getting a healthcare insurance denial, often times finding no ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Sixteen “safer” Ideal GASV emerged as buys for July. Top-ten tickers to buy were: CALM; FSK; MPLX; ET; YRD; ING; MO; VZ; NWBI ...

Pfizer saw a staggering increase in call options trading, with investors snapping up 539,824 contracts, marking a 286% jump ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) have gained a positive opinion from the European Medicines Agency’s Committee ...

New capital, maturing pipelines, and a more global R&D mindset are pushing valuations higher, even as competition tightens.

These five blue-chip dividend stocks have had a tough 2025 but are solid long-term buys for growth and income investors.

Pfizer (PFE) is currently under significant scrutiny due to a study linking its product, Depo-Provera, to increased health risks, and an associated Multi-District Litigation could have influenced its ...

Bristol Myers (BMY) delivered an impressive performance in the past month after being under pressure for quite some time. The ...

Second-quarter earnings come amid many high-level challenges for the biopharma industry. How will these five closely watched ...

PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.